

1 Quantification of Fundus
2 Autofluorescence Features in a
3 Molecularly Characterized Cohort of
4 More Than 3500 Inherited Retinal
5 Disease Patients from the United
6 Kingdom

7 William Woof^{1,2*}, Thales A. C. de Guimarões^{1,2*}, Saoud Al-Khuzaei^{3*}, Malena Daich Varela^{1,2*},
8 Sagnik Sen^{2,1*}, Pallavi Bagga^{1,2}, Bernardo Mendes^{1,2}, Mital Shah^{1,2}, Paula Burke⁴, David
9 Parry⁴, Siying Lin^{1,2}, Gunjan Naik^{1,2}, Biraja Ghoshal^{1,2}, Bart Liefers^{1,9}, Dun Jack Fu^{1,2},
10 Michalis Georgiou^{1,2}, Quang Nguyen^{1,2}, Alan Sousa da Silva², Yichen Liu¹, Yu Fujinami-
11 Yokokawa⁷, Dayyanah Sumodhee^{1,2}, Praveen Patel^{1,2}, Jennifer Furman¹, Ismail Moghul^{1,2},
12 Mariya Moosajee^{1,2}, Juliana Sallum⁸, Samantha R. De Silva³, Birgit Lorenz⁵, Frank Holz⁶,
13 Kaoru Fujinami⁷, Andrew R Webster^{1,2}, Omar Mahroo^{1,2}, Susan M. Downes³, Savita
14 Madhusudhan⁴, Konstantinos Balaskas^{1,2*}, Michel Michaelides^{1,2*}, Nikolas Pontikos^{1,2*}

15

16 ¹ University College London Institute of Ophthalmology, 11-43 Bath Street, London , UK

17 ² Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK

18 ³ Oxford Eye Hospital, John Radcliffe Hospital, Oxford OX3 9DU, UK

19 ⁴ St Paul's Eye Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool , UK

20 ⁵ Transmit Centre of Translational Ophthalmology, Justus-Liebig-Universität Giessen, Germany

21 ⁶ Department of Ophthalmology, University Hospital Bonn, Bonn, Germany.

22 ⁷ Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs,
23 National Hospital Organization Tokyo Medical Center

24 ⁸ Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Federal University
25 of Sao Paulo

26 ⁹ Department of Ophthalmology and Epidemiology, Erasmus MC, Rotterdam, The Netherlands

27

28 * Authors contributing equally

29

30 Corresponding author: n.pontikos@ucl.ac.uk

31

32 Abstract

33 **Purpose:** To quantify relevant fundus autofluorescence (FAF) image features cross-
34 sectionally and longitudinally in a large cohort of inherited retinal diseases (IRDs) patients.

35 **Design:** Retrospective study of imaging data (55-degree blue-FAF on Heidelberg Spectralis)
36 from patients.

37 **Participants:** Patients with a clinical and molecularly confirmed diagnosis of IRD who have
38 undergone FAF 55-degree imaging at Moorfields Eye Hospital (MEH) and the Royal
39 Liverpool Hospital (RLH) between 2004 and 2019.

40 **Methods:** Five FAF features of interest were defined: vessels, optic disc, perimacular ring of
41 increased signal (ring), relative hypo-autofluorescence (hypo-AF) and hyper-
42 autofluorescence (hyper-AF). Features were manually annotated by six graders in a subset
43 of patients based on a defined grading protocol to produce segmentation masks to train an
44 AI model, AIRDetect, which was then applied to the entire MEH imaging dataset.

45 **Main Outcome Measures:** Quantitative FAF imaging features including area in mm² and
46 vessel metrics, were analysed cross-sectionally by gene and age, and longitudinally to
47 determine rate of progression. AIRDetect feature segmentation and detection were validated
48 with Dice score and precision/recall, respectively.

49 **Results:** A total of 45,749 FAF images from 3,606 IRD patients from MEH covering 170
50 genes were automatically segmented using AIRDetect. Model-grader Dice scores for disc,
51 hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68 and 0.65. The
52 five genes with the largest hypo-AF areas were *CHM*, *ABCC6*, *ABCA4*, *RDH12*, and *RPE65*,
53 with mean per-patient areas of 41.5, 30.0, 21.9, 21.4, and 15.1 mm². The five genes with the
54 largest hyper-AF areas were *BEST1*, *CDH23*, *RDH12*, *MYO7A*, and *NR2E3*, with mean
55 areas of 0.49, 0.45, 0.44, 0.39, and 0.34 mm² respectively. The five genes with largest ring
56 areas were *CDH23*, *NR2E3*, *CRX*, *EYS* and *MYO7A*, with mean areas of 3.63, 3.32, 2.84,
57 2.39, and 2.16 mm². Vessel density was found to be highest in *EFEMP1*, *BEST1*, *TIMP3*,
58 *RS1*, and *PRPH2* (10.6%, 10.3%, 9.8%, 9.7%, 8.9%) and was lower in Retinitis Pigmentosa
59 (RP) and Leber Congenital Amaurosis genes. Longitudinal analysis of decreasing ring area
60 in four RP genes (*RPGR*, *USH2A*, *RHO*, *EYS*) found *EYS* to be the fastest progressor at
61 -0.18 mm²/year.

62 **Conclusions:** We have conducted the first large-scale cross-sectional and longitudinal
63 quantitative analysis of FAF features across a diverse range of IRDs using a novel AI
64 approach.

65
66
67

68 Introduction

69 Inherited retinal diseases (IRDs) are clinically and genetically heterogeneous disorders that
70 affect the retina and represent the leading cause of legal blindness among working-age
71 adults in England and Wales, and the second commonest cause in childhood¹. A recent
72 study from Austria, covering nine federal states, has also shown that IRDs are now the
73 leading cause of registered blindness in Austrian children and working-age adults². This
74 group of disorders can be caused by genetic variants in any one of over 300 genes³⁻⁵.

75

76 Many IRDs are associated with structural changes within the retina, which can be detected
77 with retinal imaging using different imaging modalities such as colour fundus, infrared-
78 reflectance (IR), spectral-domain optical coherence tomography (SD-OCT), or fundus
79 autofluorescence (FAF). FAF is of particular importance in the context of IRDs, as it allows
80 the detection of patterns of fluorophores, often at the level of the photoreceptors and retinal
81 pigment epithelium (RPE), which can be indicative of pathological changes such as loss of
82 overlying photoreceptors^{6,7}. Some of these FAF signal changes are highly characteristic of
83 specific IRDs and can indicate features such as areas of RPE atrophy or lipofuscin deposits.
84 FAF is listed as a primary or secondary outcome in multiple clinical trials, and it has become
85 a useful retinal biomarker for diagnostic and prognostication purposes in a wide variety of
86 IRDs^{4,6,8,9}.

87

88 The identification and quantification of disease-associated features within retinal imaging is
89 critical for diagnosis, monitoring disease progression, providing prognostic information and
90 assessing treatments in IRDs. The first steps in quantifying retinal imaging-based
91 biomarkers of disease involves identification and segmentation of these features. Manual
92 segmentation performed by human annotators is time-consuming and requires expert
93 annotators, which makes this process subjective and not feasible on a large scale.
94 Automated identification and segmentation of IRD features in a reliable way is important for
95 enabling the routine use of these data quantitatively in clinical practice and to help further
96 our understanding of these diseases.

97

98 Existing studies that have used deep learning to segment IRD features from retinal images
99 have so far focused on specific IRD phenotypes such as retinitis pigmentosa (RP), Stargardt
100 (STGD1), and choroideremia (CHM)^{10,11}.

101

102 To support our analysis on a broad range of different IRD phenotypes, we developed
103 AIRDetect, a deep learning model that can automatically identify and segment relevant
104 features from FAF images. We apply AIRDetect to the entire cohort of IRD patients with

105 molecularly confirmed diagnoses at Moorfields Eye Hospital (MEH), to identify genotype-
106 phenotype associations, as well as quantify disease progression.
107

108 **Methods**

109 **Dataset Curation**

110 Patients' genotypes were extracted from the Genetics database of MEH (London, UK)^{3,12}.
111 Patients' images were exported from the Heidelberg Imaging (Heyex) database (Heidelberg
112 Engineering, Heidelberg, Germany) based on their hospital number, for records between
113 2004-06-17 and 2019-10-22. All 55-degree FAF images were 488nm blue-FAF images
114 captured by the Heidelberg Spectralis and the HRA2 imaging platforms.
115
116 A dataset of 736 blue-FAF images (55-degree) from 573 patients from MEH were annotated
117 with four different image features, optic disc, regions of hyper- and hypo-autofluorescence
118 (AF), and perimacular ring of increased signal, and a further set of 206 blue-FAF images
119 (55-degree) from 127 patients from the Royal Liverpool Hospital (RLH) were annotated with
120 the retina vessel tree. A grading protocol was defined for IRD retinal feature annotations
121 (**Table 1**)¹³. The Dice similarity coefficient score was used to assess inter-grader agreement
122 ¹⁴. The Dice similarity coefficient is defined as twice the area of overlap between two
123 annotations divided by the total area occupied by the two annotations. It ranges from one for
124 perfect overlap between two annotations to zero for no overlap between two annotations.
125 The intergrader agreement was not found to be significantly different between the graders.
126 Manual grading was completed over an 18-month period from June 2022 to December 2023
127 by four graders, with two additional graders carrying out the vessel segmentation at RLH.
128 The four MEH graders were research fellows with over 5 years' experience in medical retina,
129 three of which had 3 years' experience with FAF scans and IRDs. The two RLH graders
130 were staff from the RLH Reading Centre with over 5 years' experience in vessel annotation
131 on FAF scans. Manual grading was performed using the Moorfields Grading Portal online
132 platform (grading.readingcentre.org). A full breakdown of the manually annotated dataset is
133 given in **Supplementary Table 1**.
134
135

| Name | Shorthand | Includes | Excludes |
|--------------------------------------|-----------|--|--|
| Optic Disc | disc | The optic nerve head. Includes both the optic cup and rim. | Peripapillary atrophy not included in annotation. |
| Hypo-autofluorescence | hypo-AF | Areas distinctly darker than physiological normal area with 50% grader confidence. The level of hypo-AF should be at least 90-100% as dark as the optic disc. This is defined as Definitely Decreased AF (DDAF) in the literature ^{15,16} Note this is relative AF rather than absolute AF. | Excludes peripapillary atrophy. Areas of ambiguous (not definitely decreased) regions in the periphery are not annotated as hypo-AF. |
| Hyper-autofluorescence | hyper-AF | Regions brighter than physiological normal area with 50% grader confidence. Note this is relative AF rather than absolute AF. | Excludes macular ring. Excludes flecks. |
| Perimacular ring of increased signal | ring | Ring shaped area of hyper-AF within the vascular arcades at the macula. | Must be >50% complete circle. |
| Veins and Arteries | vessels | All visible retinal vessels stemming from the optic disc. | Only annotated over atrophy if the grader is more than 50% certain of the location of the vessel. |

136 **Table 1:** Features and definitions used during the annotation process of five features by the graders.

137

138

139 Training and Test Datasets

140 The annotated dataset was compiled, and any images without confirmation for all features
141 from at least one grader at the time of model development were discarded, and, to avoid
142 bias, the annotation from a single grader was randomly selected where multiple grader
143 annotations were available for a single image. After this process there were 554 images from
144 464 patients from MEH. The MEH training set consisted of 506 images from 424 patients.
145 The MEH hold-out test set consisted of 48 images from 40 patients. The RLH training set
146 consisted of 72 images from 52 patients from RLH. The RLH hold-out test set consisted of
147 23 images from 22 patients. Training sets were split into five separate sets for use with 5-fold
148 cross validation, ensuring a balanced representation of each class across folds. Assignment
149 to the training and test sets was done at patient-level to avoid any potential data leakage.
150 The data flowchart is fully described in **Supplementary Figure 1**.

151

152 Development of AIRDetect Segmentation Model

153 For training the AIRDetect segmentation model, we selected the nnU-Net (no-new-UNet)
154 framework for its adaptability and performance in automatic medical image segmentation
155 tasks¹⁷. At its core, nnU-Net leverages a fully convolutional network design inspired by the

156 U-Net architecture, renowned for its efficacy in medical imaging tasks¹⁸⁻²⁰. The overlying
157 nnU-Net framework then automatically configures its network architecture, preprocessing,
158 and training strategy based on the dataset's characteristics, optimising for performance,
159 without requiring manual hyperparameter tuning or architecture modifications from the user.

160

161 For the five different image features, we trained two separate nnU-net models. A single
162 multi-class model for disc, hyper-AF and hypo-AF, and ring, and a separate single-class
163 model for vessels. As with common practice for nn-Unet each model consisted of an
164 ensemble of five U-nets with identical architectures, but different weights, trained
165 independently and then ensembled at inference, taking the unweighted average of the
166 probability scores across networks.

167

168 The model was trained using a sum of Dice and cross-entropy loss functions to optimise for
169 multi-class segmentation accuracy. Hyperparameters, such as learning rate and batch size,
170 were selected by the nnU-Net based on its analysis of the dataset. Training was curtailed at
171 200 epochs as this was sufficient to achieve convergence in most cases.

172

173 Validation of AIRDetect Segmentation Model

174 Model validation was assessed using the Dice coefficient between the model predictions and
175 the corresponding grader annotation on the hold-out test set. Where images were double-
176 graded, we took the mean of the model-grader Dice for each grading. We also analysed the
177 accuracy of the model-grader agreement for simple presence/absence detection where we
178 counted cases as positive for which the model/annotator marked at least some part of the
179 image for the given feature, and negative otherwise, from which we derived
180 presence/absence detection accuracy, precision and recall.

181 Automatic Annotations on Real World IRD Dataset

182 The trained models were applied to automatically segment 45,749 FAF images (55-degree)
183 from 3,606 IRD patients with a molecularly confirmed diagnosis from MEH covering 170
184 genes^{3,12}. This took on average 1 second per image parallelised over four 3090 Nvidia
185 GPUs amounting to approximately 3-4 hours in total. In comparison a human grader could
186 take 5-30 minutes per scans amounting to 5-3 months in total. Images where the optic disc
187 was not segmented by the model were removed, as these images were of poor quality or not
188 centred on the macula (**Supplementary Figure 2**). Results were analysed from 33,042 FAF
189 images from 3,496 patients, after filtering.

190

191 For each of the generated masks we extracted: a) if the feature was present or absent; b)
192 the area, number of pixels in the segmented mask multiplied by the resolution; c) the number
193 of connected components, found using watershed clustering²¹; d) feature brightness, mean
194 intensity of pixels from the region covered by the segmented mask. For vessels, we
195 calculated a selection of metrics defined in **Supplementary Table 2**, using the provided
196 code from the reti-py library as used in the AutoMorph repository²². Features were also
197 analysed based on their distance from the fovea.

198

199 To calculate rate of progression for a given feature, a linear regression was fit to each
200 patient-eye, taking time since the first appointment (in years) as the independent variable,
201 and taking the calculated areas of the segmented feature at each time-point as the
202 measured variable. The slope of the regression was then averaged across eyes per-patient
203 to give a rate of progression. Where multiple scans per eye were present for a given date,
204 we took the most recent scan with the rationale that good quality scans were less likely to
205 lead to further imaging by the operator.

206

207 Results


208 AIRDetect Model Validation

209

210 Examples of AIRDetect segmentation output are presented in **Figure 1**. Model-grader Dice
211 scores for disc, hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68
212 and 0.65, with intergrader Dice scores of 0.82, 0.75, 0.72, 0.80, 0.95, respectively. Model
213 detection accuracy ranged from 77% to 83% (excluding anatomical features) (**Table 2**).

214 Features which were the most challenging to detect were hyper-AF and ring as those had
215 the lowest precision scores at 0.53 and 0.60 respectively.

216



217

218

219

220

221

222

223

Figure 1: Examples of manually and automatically segmented masks for the five features: vessels, disc, ring, hyper- and hypo-autofluorescence. The vessel dataset was separate to the rest of the data, so vessel visualisation is separate from other features.

225 **Table 2:** Segmentation model training data and results. Dice score quantifies the model's
 226 segmentation performance and presence/absence quantifies its feature detection performance. Total
 227 = number of annotated images. Incidence = percent of images with gradable feature. Dice inter-grader
 228 = inter-grader agreement of double-graded images (repeated from **Table 2** for reference). Dice model-
 229 grader = Dice score between model and graders, with mean scores used when images were double-
 230 graded.

| Feature | Train set | | Test Set | | Segmentation (Dice) | | Detection (Presence/Absence) | | |
|----------|-----------|-----------|----------|-----------|---------------------|--------------|------------------------------|-----------|--------|
| | Total | Incidence | Total | Incidence | Inter-grader | Model-grader | Accuracy | Precision | Recall |
| disc | 506 | 98% | 48 | 98% | 0.82 | 0.86 | - | - | - |
| hypo-AF | 506 | 70% | 48 | 44% | 0.75 | 0.72 | 83.3% | 0.81 | 0.81 |
| hyper-AF | 506 | 18% | 48 | 23% | 0.72 | 0.69 | 79.2% | 0.53 | 0.82 |
| ring | 506 | 32% | 48 | 31% | 0.80 | 0.68 | 77.1% | 0.60 | 0.80 |
| vessels | 72 | 100% | 23 | 100% | 0.94 | 0.65 | - | - | - |


231

232 Genotype-phenotype Associations

233

234 Analysing associations between identified features and genes across most common genes
 235 (**Supplementary Table 3**), the five genes with the largest hypo-AF areas were *CHM*,
 236 *ABCC6*, *ABCA4*, *RDH12*, and *RPE65*, with mean per-patient areas of 41.5, 30.0, 21.9, 21.4,
 237 and 15.1 mm² (**Figure 2a**). The five genes with the largest hyper-AF areas were *BEST1*,
 238 *CDH23*, *RDH12*, *MYO7A*, and *NR2E3*, with mean areas of 0.49, 0.45, 0.44, 0.39, and 0.34
 239 mm² respectively (**Figure 2b**). The five genes with largest ring areas were *CDH23*, *NR2E3*,
 240 *CRX*, *EYS* and *MYO7A*, with mean areas of 3.63, 3.32, 2.84, 2.39, and 2.16 mm² (**Figure**
 241 **2c**). At the gene variant level, *ABCA4* p.(Gly1961Glu) showed a higher ring area than other
 242 common *ABCA4* variants (**Supplementary Figure 4**). Vessel density was found to be
 243 highest in *EFEMP1*, *BEST1*, *TIMP3*, *RS1*, and *PRPH2* (10.6%, 10.3%, 9.8%, 9.7%, 8.9%)
 244 and was lower in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis associated
 245 genes (**Figure 2d**). A full breakdown of features across the 30 most common genes is given
 246 in **Supplementary Table 3**, for all genes in **Supplementary Table 4** and for vessels in
 247 **Supplementary Table 5**.

248



249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267


268

269

270

Figure 2: Mean **a)** extent of hypo-AF, **b)** extent of hyper-AF, **c)** extent of ring, and, **d)** Vessel density (ratio between area of vessels and total image area) across the 30 most common genes (*RPE65* included for reference). Error bars denote standard error. Values were first averaged by patient before averaging by gene to minimise correlations due to multiple contributions from individual patients. Genes are grouped into approximate phenotype groupings denoted by bar styling.

We analysed how features vary with distance from the fovea by looking at the prevalence of each feature in each 0.5 mm annulus moving away from the fovea. **Figure 3** compares prevalence of hyper- and hypo-AF at different distances from the fovea in five different genes (see **Supplementary Figure 7** for scale). The two genes associated largely with maculopathy or cone-rod dystrophy (*ABCA4*, *PRPH2*) show increased area and prevalence of hypo-AF at the fovea (**Figure 3.a** and **Figure 2.a**) but reducing proportions of the retina displaying hypo-AF moving away from the fovea. The two RP-associated genes (*USH2A*, *RPGR*) show less hypo-AF across the whole retina compared with the cone-rod genes, but with a bimodal profile, with the greatest relative proportion of hypo-AF at the fovea followed by 4-6mm from the fovea, just within the vascular arcade. For *CHM*, unlike the other genes, there was the least hypo-AF at the fovea, but substantially increased hypo-AF away from the fovea. For hyper-AF there is an increased proportion of hyper-AF at the fovea in all genes except *ABCA4* that reduces further from the fovea (**Figure 3b**). In the two RP-associated genes (*USH2A*, *RPGR*) there is an increase in hyper-AF at 1-3mm from the fovea.




271
272
273
274
275

Figure 3: Autofluorescence (AF) as a proportion of total altered AF area in the image compared with distance from fovea for patients with variants in *ABCA4*, *RPGR*, *USH2A*, *RPGR*, and *CHM* for a) hypo-AF and b) hyper-AF.

276 In **Figure 4** the area of hyper-AF within 1.5mm of the fovea is compared against patient age
277 for five different IRD genes. Most genes showed an increase with age, with the exception of
278 *PRPH2*, which remained fairly stationary, and *BEST1*, which demonstrated a sharp
279 decrease with patient age - although there was a considerable variability across ages within
280 all genes.

281



282
283
284
285
286
287
288
289
290
291

Figure 4: hyper-AF area within 1.5mm of the fovea (corresponding to inner 3mm ETDRs ring) compared with patient age. Least-squares regression line in red. Significant increase in hyper-AF with age for *ABCA4* ($\beta=691 \mu\text{m}^2/\text{yr}$, $p<0.001$), *USH2A* ($\beta=4090 \mu\text{m}^2/\text{yr}$, $p<0.001$) and *RPGR* ($\beta=2520 \mu\text{m}^2/\text{yr}$, $p<0.029$). Significant decrease for *BEST1* ($\beta=-6500 \mu\text{m}^2/\text{yr}$, $p<0.001$). No significant changes of hyper-AF with age were found for *PRPH2*.

292


293 Disease Progression

294 We applied AIRDetect longitudinally to monitor progression within individual patients across
295 multiple visits. **Figure 5** shows an example using AIRDetect to visualise the decrease in ring
296 area in individual patients with RP associated with variants in four different genes, namely
297 *USH2A*, *PRPH2*, *RHO* and *EYS*. Comparing these four RP genes in the entire MEH IRD
298 cohort, average rate of decrease in total ring area was greater in patients with RP associated
299 with *EYS* ($-0.178 \text{ mm}^2/\text{year}$), *USH2A* ($-0.066 \text{ mm}^2/\text{year}$), and *RPGR* ($-0.046 \text{ mm}^2/\text{year}$), when
300 compared to *RHO* ($-0.040 \text{ mm}^2/\text{year}$).

301


302 We also applied AIRDetect to monitor progression in patients belonging to three subgroups
303 of *ABCA4* (**Figure 6**). Patients were classified into three groups (A, B and C) based on
304 increasing severity of genetic variants as defined by Cornelis et al.^{23,24}. Patients in group A
305 had two severe variants, while group C had a mild variant in trans with any other variant.
306 Patients with variants of known severity whose combination do not fit the other two groups
307 were placed into group B. The average increase in hypo-AF area per year was compared
308 between groups (**Supplementary Figure 3**). In keeping with previous studies^{25–29}, the mean
309 per-patient rate of increase in hypo-AF area was highest in the highest severity classification
310 (group A), at $3.11 \text{ mm}^2/\text{year}$ ($0.294 \text{ mm}/\text{year}$ change in square root area), followed by 1.59
311 mm^2/year ($0.169 \text{ mm}/\text{year}$) for the intermediate severity group (B), and finally $0.87 \text{ mm}^2/\text{year}$
312 ($0.108 \text{ mm}/\text{year}$) in the lowest severity group (C) (**Supplementary Table 6**).

313



314

315 **Figure 5:** Automatic monitoring of lesion size for disease progression. Decreasing area of ring for four
316 patients with disease-causing variants in: a) *RPGR*, b) *USH2A*, c) *RHO*, and d) *EYS*. In these genes,
317 the macular ring is expected to shrink in diameter over time as the disease progresses.
318



319 **Figure 6:** Increasing area of hypo-AF for two patients of each of the three *ABCA4* severity groups: a)
320 group A, b) group B and c) group C. Here we see the expected patterns of progression reported in
321 **Supplementary Table 6** with A being the fast progressors, followed by B and C.
322

323 Discussion

324 The results of our cross-sectional analysis match known genotype-phenotype associations
325 demonstrating the validity of our approach, as well yielding novel insights. For example in
326 **Figure 2.a**, *CHM* and *ABCA4* both exhibited higher levels of hypo-AF, consistent with the
327 large areas of atrophy that spare the fovea in choroideremia, as well as the macular atrophy
328 typically seen in STGD1 disease (*ABCA4*)^{8,30-32}. Of interest however, *ABCC6* which is
329 associated with pseudoxanthoma elasticum was identified to have second largest areas of
330 hypo-AF. On further inspection, these could be explained by the large angioid streaks
331 characteristic of this condition which can appear as hypo-AF on FAF³³. For hyper-AF, *BEST1*
332 exhibited the largest areas of hyper-AF, which can be attributed to the vitelliform lesion(s)
333 that are characteristically observed in autosomal dominant and recessive forms of the
334 disease³⁴⁻³⁶ (**Figure 2.b**). For ring the presence of a macular ring typically corresponds to a
335 demarcation between diseased and non-diseased retina, and is usually seen in RP and cone
336 rod dystrophies, in keeping with our findings herein⁴ (**Figure 2.c**). The lower vessel density
337 observed in RP and LCA genes was also in keeping with the vessel attenuation commonly
338 associated with these genes^{37,38} (**Figure 2.d**). As well as genotype-phenotype associations,
339 we also found associations at the individual variant level confirming known association
340 between the p.(Gly1961Glu) variant in *ABCA4* and presence of a macular ring³⁹⁻⁴²
341 (**Supplementary Figure 3**). When considering feature prevalence from the fovea, we found,
342 as expected, that genes usually associated with cone-rod degeneration showed a decrease
343 in hypo-AF extent moving away from the fovea, but with an opposite trend for the RP genes
344 and *CHM* (**Figure 3**). Hyper-AF was mainly concentrated at the fovea, but with a distinctive
345 peak at 2-3mm from the fovea which may be attributed to partial macular rings classified as
346 hyper-AF by our model (**Figure 3.b**). *PRPH2* also had a higher coverage of hyper-AF in the
347 fovea when compared to *ABCA4* which is consistent with the pattern/macular dystrophy and
348 adult vitelliform phenotypes associated with *PRPH2*⁴³ (**Figure 3.b**).

349
350 In our longitudinal analysis we were able to replicate the findings of Fakin *et al.* 2016 in
351 **Figure 7** and **Table 4**, where we found that growth of areas of hypo-AF was much more
352 rapid in the group associated with more severe *ABCA4* genetic variants²⁵. Our estimates for
353 rate of progression were higher than that previously reported, which may be due to the use
354 of 55-degree as opposed to 30-degree imaging in our dataset and hence a larger area of
355 hypo-AF^{28,44}. Comparing hyper-AF across patient age in **Figure 4**, the hyper-AF within
356 1.5mm of the fovea increased for *ABCA4*, *USH2A* and *RPGR*, consistent with lesions
357 developing with disease progression over time. However, there were some noteworthy
358 exceptions for individual genes. In particular, *BEST1* is associated with “yolk-like” regions of
359 hyper-AF, typically within 2-3 mm of the perifovea, which change over time through pre-

360 vitelliform, vitelliform, pseudohypopyon, vitelliruptive stages and finally to the atrophic stage
361 ^{4,36}. The highest hyper-AF signal would be associated with the vitelliform stage, progressively
362 reducing in intensity to become a region of hypo-AF by the atrophic stage, which matches
363 what we see as a decrease in foveal hyper-AF with age. No significant progression of
364 hyper-AF with age was detected for *PRPH2* which is likely due to the later onset of the
365 condition in most patients (typically after 45 years of age) and hence a more limited age
366 range, as well as the milder pattern of dystrophy ⁴⁵

367

368 We also identified increased rate of decrease in area of macular ring in *EYS*, *USH2A* and
369 *RPGR* compared to *RHO* (**Figure 6**). Monitoring the rate in which the macular ring narrows
370 down is common practice in generalised retinal dystrophies such as RP ⁶. A more rapid
371 encroachment of the macular ring in autosomal recessive (*USH2A*, *EYS*) and X-linked
372 (*RPGR*) genes compared to the autosomal dominant *RHO*, is consistent with the latter
373 having a slower disease progression compared to the others ⁴⁶.

374

375 To date, deep learning AI models to analyse FAF images from IRD patients have been
376 limited. There have been studies developing classification models of FAF images based on
377 IRD phenotypes ⁴⁷⁻⁵⁰. But as to segmentation approaches, areas of hypo-AF have been
378 measured either manually or semi-automatically using RegionFinder on HEYEX2 software
379 to study the progression rate of the area of atrophy in STGD1 disease ⁵¹⁻⁵⁴. These
380 approaches compared to deep-learning approaches would be challenging to scale
381 accurately to our real-world dataset as they require considerable parameter tuning compared
382 to deep-learning based approaches such as AIRDetect. Previous deep-learning based
383 segmentation approaches have mostly focused on STGD1 to segment for hypo-AF⁵⁵ or
384 flecks¹¹. Hence our AIRDetect approach represents the first to be developed and applied to
385 a wide range of IRDs covering 170 genes.

386

387 One limitation of our approach is that the gene associations described in our study are
388 limited by the variation in phenotypes which can occur with stage of disease for progressive
389 conditions, different variants in the same gene or different modes of inheritance. Examining
390 distribution of best corrected visual acuity per gene in our data, we can confirm that a range
391 of disease stages are present in our dataset (**Supplementary Figure 8**). In terms of
392 examples of phenotype variability per gene, *CRX* can be associated with a mild CORD but
393 also quite severe LCA ⁵⁶⁻⁵⁸. *RPGR* can be associated with RP, LCA, macular dystrophy and
394 CORD ^{59,60}. We conducted a sub analysis in *ABCA4* (**Supplementary Figure 4**) but have
395 not yet conducted this analysis across all gene variants and modes of inheritance.

396

397 Other limitations are the limited sample size for some of the genes and the large variance in
398 imaging quality in our real-world dataset in part due to the discomfort of the patient to
399 potential blue light-toxicity⁶¹, which affects the reliability of some of the features in lower
400 quality images. While automatic image quality assessment tools exist for colour fundus
401 retinal imaging⁶², none have been developed for FAF imaging. Assessing image quality can
402 also be particularly challenging for IRDs as they are associated with a wide range of
403 pathologies, many of which can affect perceived image quality, as well as make it more
404 challenging for the operator to acquire good quality images. We plan to develop an IRD FAF
405 image quality assessment model in future, which should help to improve the consistency of
406 our segmented masks and reduce noise in our analysis.

407

408 We anticipate that AIRDetect can be used to validate further clinically relevant findings, as
409 well as identifying new potential associations between different feature patterns and certain
410 genes or variants. Our approach could also be applied to identifying structure-function
411 association (**Supplementary Figure 5**) as well as cross-modality image registration tasks by
412 using vessel-based segmentation to align images (**Supplementary Figure 6**). Besides
413 IRDs, the diverse nature of IRD-associated pathologies might make AIRDetect useful to
414 improve robustness for segmentation of FAF imaging for other non-IRD conditions or provide
415 a good starting point for developing models for specific conditions where data is more scarce
416 or to other imaging modalities such as ultra-widefield imaging, via transfer learning.

417

418 In conclusion, we have conducted, to our knowledge, the largest quantitative cross-sectional
419 and longitudinal analysis of FAF features across a diverse range of IRDs in a real world
420 dataset, enabled by our novel automatic segmentation AI model, AIRDetect.

421 Ethics

422 This research was approved by the IRB and the UK Health Research Authority Research
423 Ethics Committee (REC) reference (22/WA/0049) "Eye2Gene: accelerating the diagnosis of
424 inherited retinal diseases" Integrated Research Application System (IRAS) (project ID:
425 242050). All research adhered to the tenets of the Declaration of Helsinki.

426

427 Code availability

428 The source code for the AIRDetect model architecture training and inference is available
429 from <https://github.com/Eye2Gene/>. The model weights of AIRDetect are intellectual
430 proprietary of UCLB so cannot be shared publicly. However, they may be shared via a
431 licensing agreement with UCLB. A running version of the AIRDetect app is accessible via the

432 Eye2Gene website (www.eye2gene.com) and via the Moorfields Grading Portal
433 (grading.readingcentre.org) on invitation.
434

435 Data availability

436 The data that support the findings of this study are divided into two groups, published data
437 and restricted data. Published data are available from the Github repository. Restricted data
438 are curated for AIRDetect users under a license and cannot be published, to protect patient
439 privacy and intellectual property. Synthetic data derived from the test data has been made
440 available at <https://github.com/Eye2Gene/>.

441

442 Author contributions

443 WAW analysed the data and wrote the manuscript. NP designed the obtained the funding,
444 designed the experiments, analysed data and wrote the manuscript. MM, KB, WAW, TACG,
445 SAK, MDV, BM designed the experiments, analysed data and wrote the manuscript. SS
446 analysed the data. MS wrote the manuscript. PBa analysed the data. PBU, DP analysed the
447 data. All authors have critically reviewed the manuscript.


448 Acknowledgement

449 This work is primarily funded by a NIHR AI Award (AI_AWARD02488) which supported NP,
450 WAW, MM, KB, SD and SM. The research was also supported by a grant from the National
451 Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Moorfields Eye
452 Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. NP was also previously
453 funded by Moorfields Eye Charity Career Development Award (R190031A). BJ was partially
454 funded by IIR-DE-002818 from Shire/Takeda and by the European Reference Network for
455 Rare Malformation Syndromes, Intellectual and Other Neurodevelopmental Disorders (ERN-
456 ITHACA). OAM is supported by the Wellcome Trust (206619/Z/17/Z). AYL is supported by
457 an unrestricted and career development award from RPB, Latham Vision Science Awards,
458 NIH OT2OD032644, NEI/NIH K23EY029246, and NIA/NIH U19AG066567. SA is supported
459 by a scholarship from Qatar National Research Fund (GSRA6-1-0329-19010). This project
460 was also supported by a generous donation by Stephen and Elizabeth Archer in memory of
461 Marion Woods. The hardware used for analysis was supported by the BRC Challenge Fund
462 (BRC3_027). We also gratefully acknowledge the support of NVIDIA Corporation with the
463 donation of the Titan Xp GPU used for this research. The views expressed are those of the
464 authors and not the funding organisations.

465


466 **Supplementary**

467 **Supplementary Figure 1:** Data flowchart with number of images, patients, eyes, and genes at each
 468 stage of AIRDetect model development.



469
 470
 471

472 **Supplementary Figure 2:** Examples of images with no Disc segmentation from the model. These are
473 either poor quality, have significant atrophy, or are improperly centred.
474



475
476

477 **Supplementary Table 1:** Overview of annotated dataset for the manually segmented features,
 478 considering each feature individually. Not all features were gradable within all images, with some
 479 images only annotated for some features. Images for vessel annotations were selected by clinicians
 480 and were all gradable. Incidence includes ungradable

| Feature | Graded | Double graded | Partially Gradable | Un-Gradable | Num Patients | Num Genes | Present | Incidence |
|----------|--------|---------------|--------------------|-------------|--------------|-----------|---------|-----------|
| disc | 736 | 207 | 74 | 32 | 573 | 63 | 716 | 97.3% |
| hypo-AF | 736 | 204 | 75 | 32 | 573 | 63 | 482 | 65.5% |
| hyper-AF | 730 | 191 | 77 | 32 | 570 | 63 | 106 | 14.5% |
| ring | 729 | 195 | 76 | 32 | 571 | 63 | 212 | 29.1% |
| vessels | 206 | 13 | <i>n/a</i> | <i>n/a</i> | 127 | 33 | 206 | 100% |

481
 482
 483

Supplementary Table 2: Vessel metrics and their description.

| Vessel Metric | Description |
|------------------------------|--|
| Fractal Dimension | Method that represents geometric complexity of the vascular branching pattern observed in the retina. Essentially how close are the vessels to being “space-filling”. |
| Vessel Density | Ratio between area of vessels and total image area. |
| Average Width | Average width of vessels. |
| Distance Tortuosity | Distance tortuosity is a measure of the tortuosity of a path based on the ratio of the actual path length to the straight-line distance between the start and end points of the path ⁶³ |
| Squared Curvature Tortuosity | Squared curvature tortuosity is a more sophisticated measure of tortuosity that takes into account the curvature along the path, providing a detailed view of its winding nature ⁶³ |
| Tortuosity Density | Assesses vessel tortuosity by aggregating local contributions, examining the degree to which each turn curve deviates from a smooth curve ⁶⁴ |

484
 485

Supplementary Table 3: Feature statistics by gene for selected 30 genes. Results are mean across all images. %=Incidence, A=Average Area (mm²), C=Num Components, I = Intensity (pixel brightness), <3mm=Proportion of feature area within 3mm of the fovea (corresponding to outer 6mm ETRDS ring), D=vessel density, F=fractal dimension. The table cells have been shaded with lower values in red, intermediate values in white and larger values in green.

| Gene | disc | | | | hypo-AF | | | | | hyper-AF | | | | | ring | | | | vessels | | |
|---------|------|------|--------|--------|---------|-------|------|--------|--------|----------|------|------|--------|--------|--------|------|------|--------|---------|--------|------|
| | A | C | I | <3mm | % | A | C | I | <3mm | % | A | C | I | <3mm | % | A | C | I | <3mm | D | F |
| ABCA4 | 2.19 | 1.01 | 9.20% | 13.70% | 80.30% | 19.81 | 1.45 | 11.10% | 61.30% | 18.00% | 0.05 | 0.33 | 66.40% | 48.30% | 33.50% | 0.57 | 1.58 | 59.60% | 81.80% | 7.65% | 1.33 |
| ABCC6 | 1.53 | 1.03 | 16.90% | 17.60% | 69.00% | 21.44 | 2.08 | 14.30% | 32.60% | 54.90% | 0.23 | 1.2 | 62.50% | 23.40% | 8.20% | 0.03 | 0.15 | 43.30% | 38.00% | 8.07% | 1.37 |
| BBS1 | 2.59 | 1.02 | 10.40% | 7.50% | 67.50% | 8.35 | 1.29 | 11.90% | 56.90% | 25.90% | 0.15 | 0.38 | 47.30% | 86.90% | 32.50% | 0.84 | 1.03 | 56.50% | 72.70% | 4.56% | 1.18 |
| BEST1 | 1.84 | 1.01 | 11.60% | 4.10% | 40.50% | 2.58 | 0.9 | 11.50% | 59.70% | 57.50% | 0.73 | 1.09 | 61.20% | 59.80% | 57.50% | 1.28 | 1.83 | 56.30% | 77.20% | 9.62% | 1.38 |
| CACNA1F | 2.04 | 1.01 | 14.80% | 0.00% | 5.70% | 0.91 | 0.2 | 7.10% | 42.40% | 12.80% | 0.01 | 0.15 | 59.80% | 2.50% | 3.80% | 0.01 | 0.06 | 53.60% | 79.80% | 5.35% | 1.21 |
| CDH23 | 2.05 | 1.01 | 14.30% | 6.40% | 16.20% | 0.71 | 0.47 | 10.40% | 42.00% | 19.60% | 0.23 | 0.5 | 57.60% | 34.20% | 77.30% | 2.46 | 2.73 | 47.30% | 67.30% | 2.46% | 1.05 |
| CERKL | 2.63 | 1 | 12.30% | 9.10% | 82.30% | 10.33 | 1.43 | 12.10% | 51.70% | 17.70% | 0.02 | 0.21 | 46.00% | 88.60% | 29.70% | 1.04 | 0.95 | 58.10% | 65.30% | 3.51% | 1.16 |
| CHM | 1.45 | 1.06 | 20.60% | 2.80% | 82.60% | 51.77 | 3.28 | 19.90% | 21.00% | 48.80% | 0.26 | 0.83 | 54.50% | 37.90% | 5.50% | 0.03 | 0.08 | 43.20% | 32.20% | 6.20% | 1.3 |
| CNGA3 | 1.74 | 1.01 | 13.80% | 14.50% | 31.10% | 1.48 | 0.96 | 7.10% | 56.30% | 8.00% | 0.05 | 0.17 | 54.00% | 31.80% | 35.60% | 0.32 | 0.75 | 50.00% | 74.90% | 5.36% | 1.1 |
| CNGB3 | 1.91 | 0.99 | 14.90% | 12.70% | 12.50% | 0.16 | 0.38 | 6.70% | 73.60% | 10.40% | 0.01 | 0.12 | 52.70% | 63.90% | 32.60% | 0.2 | 0.63 | 54.60% | 92.20% | 5.92% | 1.1 |
| CRB1 | 1.97 | 1.02 | 14.70% | 3.60% | 55.20% | 8.3 | 1.22 | 15.60% | 40.40% | 44.00% | 0.41 | 0.89 | 46.40% | 54.00% | 43.70% | 1.73 | 1.35 | 48.90% | 59.20% | 4.27% | 1.1 |
| CRX | 2.11 | 1 | 15.60% | 5.70% | 70.30% | 5.51 | 1.39 | 15.60% | 62.70% | 16.90% | 0.05 | 0.26 | 50.70% | 29.90% | 59.30% | 2.23 | 4.22 | 52.90% | 65.90% | 7.30% | 1.1 |
| EFEMP1 | 1.77 | 1 | 15.30% | 6.00% | 78.70% | 5.15 | 1.84 | 14.20% | 82.40% | 77.90% | 0.24 | 1.55 | 61.80% | 79.40% | 24.10% | 0.18 | 0.66 | 60.00% | 82.50% | 10.10% | 1.1 |
| EYS | 2.36 | 1.02 | 15.20% | 2.90% | 65.90% | 9.55 | 1.64 | 13.30% | 27.30% | 23.40% | 0.23 | 0.4 | 57.60% | 42.90% | 72.50% | 2.08 | 2.76 | 52.60% | 76.80% | 3.07% | 1.1 |
| GUCY2D | 2 | 1 | 14.70% | 6.50% | 48.00% | 5.25 | 0.86 | 17.50% | 71.20% | 17.60% | 0.22 | 0.3 | 61.20% | 36.00% | 60.90% | 1.51 | 2.94 | 53.10% | 75.00% | 6.91% | 1.1 |
| MYO7A | 2.07 | 0.99 | 15.80% | 2.30% | 42.30% | 2.37 | 0.95 | 18.00% | 32.90% | 28.00% | 0.41 | 0.97 | 53.70% | 21.80% | 73.60% | 3.24 | 3.26 | 47.00% | 57.80% | 2.70% | 1.1 |
| NR2E3 | 1.94 | 1.02 | 10.90% | 7.40% | 31.50% | 1.42 | 0.76 | 10.20% | 12.90% | 21.40% | 0.37 | 0.5 | 56.50% | 17.90% | 39.60% | 1.72 | 1.4 | 52.20% | 24.70% | 8.33% | 1.1 |
| PDE6B | 2.62 | 1.01 | 14.80% | 3.40% | 52.20% | 4.48 | 0.93 | 17.00% | 49.30% | 21.30% | 0.08 | 0.28 | 55.10% | 56.90% | 86.00% | 3.37 | 4.06 | 47.30% | 86.60% | 3.00% | 1.1 |
| PROM1 | 2.3 | 1.01 | 12.60% | 7.00% | 80.00% | 12.15 | 1.72 | 12.60% | 72.00% | 21.10% | 0.04 | 0.25 | 52.30% | 72.90% | 34.80% | 0.85 | 2.06 | 54.00% | 82.50% | 6.10% | 1.1 |
| PRPF31 | 2.2 | 1.03 | 15.50% | 1.20% | 48.10% | 6.78 | 1.56 | 12.00% | 41.30% | 18.80% | 0.12 | 0.34 | 45.90% | 68.30% | 64.00% | 2.17 | 2.85 | 52.50% | 86.90% | 4.10% | 1.1 |
| PRPH2 | 2.05 | 1.01 | 12.30% | 4.50% | 68.70% | 10.28 | 1.89 | 10.10% | 62.00% | 36.40% | 0.07 | 0.58 | 59.10% | 77.10% | 26.30% | 0.69 | 0.85 | 55.80% | 69.40% | 8.00% | 1.1 |
| RDH12 | 1.92 | 1.01 | 18.00% | 11.80% | 58.10% | 22.35 | 1.1 | 19.00% | 37.30% | 33.70% | 0.37 | 0.52 | 49.00% | 22.10% | 34.10% | 1.51 | 2.52 | 57.90% | 84.80% | 2.93% | 0.9 |
| RHO | 2.17 | 1.03 | 15.50% | 1.50% | 61.90% | 9.74 | 1.72 | 13.60% | 34.80% | 18.50% | 0.11 | 0.24 | 53.00% | 56.00% | 70.60% | 2.25 | 2.99 | 53.60% | 82.80% | 4.47% | 1.1 |
| RP1 | 2.19 | 1.01 | 13.70% | 5.50% | 63.00% | 9.32 | 1.76 | 13.10% | 40.10% | 19.10% | 0.18 | 0.27 | 55.90% | 66.70% | 65.00% | 2.03 | 2.98 | 54.60% | 74.80% | 4.59% | 1.1 |
| RP2 | 2.48 | 1.05 | 9.90% | 13.30% | 47.60% | 3.1 | 1.19 | 10.50% | 48.30% | 6.90% | 0.02 | 0.08 | 54.70% | 84.40% | 13.00% | 0.26 | 0.38 | 59.00% | 67.80% | 3.65% | 1.1 |
| RPE65 | 1.15 | 1.06 | 19.30% | 7.60% | 52.40% | 40.13 | 2.65 | 15.00% | 29.10% | 37.80% | 0.24 | 0.65 | 56.40% | 61.80% | 4.90% | 0.19 | 0.05 | 43.10% | 97.60% | 2.04% | 0.97 |
| RPGR | 2.31 | 1.01 | 13.70% | 3.70% | 54.20% | 7.78 | 1.27 | 14.40% | 36.50% | 22.60% | 0.13 | 0.31 | 54.40% | 58.60% | 61.30% | 2.13 | 2.09 | 55.90% | 82.00% | 4.06% | 1.19 |
| RS1 | 1.93 | 1 | 11.90% | 3.50% | 26.80% | 2.41 | 0.58 | 10.70% | 36.70% | 24.80% | 0.1 | 0.37 | 44.30% | 73.20% | 16.90% | 0.35 | 0.59 | 53.00% | 66.40% | 8.69% | 1.34 |
| TIMP3 | 1.71 | 1.01 | 17.50% | 9.50% | 62.10% | 16.35 | 1.84 | 15.30% | 46.50% | 30.70% | 0.14 | 0.51 | 58.50% | 32.60% | 27.00% | 0.47 | 1 | 55.20% | 35.30% | 9.15% | 1.39 |
| USH2A | 2.17 | 1.02 | 15.60% | 2.30% | 61.30% | 8.47 | 1.76 | 13.00% | 36.50% | 19.80% | 0.15 | 0.31 | 53.50% | 66.50% | 72.10% | 1.98 | 3.2 | 53.50% | 87.50% | 3.42% | 1.17 |
| All | 2.09 | 1.02 | 13.50% | 6.90% | 61.20% | 13.04 | 1.46 | 13.00% | 48.20% | 25.10% | 0.15 | 0.43 | 57.10% | 52.80% | 43.70% | 1.19 | 1.78 | 54.10% | 77.90% | 5.75% | 1.25 |

medRxiv preprint doi: <https://doi.org/10.1101/2024.03.24.24304809>; this version posted August 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary Table 4: Feature statistics for all genes. Phenotypes: pheno = most common phenotype presentation according to literature. ACHM = achromatopsia, ALB = albinism, BEST = best disease, CD = cone-dystrophy, CHM = choroidemia, CR = cone-rod, CSNB = congenital stationary night blindness, DR = diabetic retinopathy, FEVR = Familial exudative vitreoretinopathy, GA = Gyrate atrophy, LCA = Leber's congenital amaurosis, MAC = Microphthalmia, anophthalmia, coloboma, MD = macular dystrophy, OA = optic atrophy, PD = pattern dystrophy, PXE = pseudoxanthoma elasticum, RP = retinitis pigmentosa. pat = number of patients. img = number of FAF images. Feature metrics are averaged across all images per gene. Features: % = average incidence in percent, A = average area in mm², C = average number of clusters, I = average pixel intensity in percentage, % <6mm = average incidence within 6mm area in percent, FD = vessel fractal dimensions, D = average vessel density, W = average vessel width, DTM = distance tortuosity mean, SCTM = squared curvature tortuosity mean, TDM = tortuosity density mean.


(see online supplementary table 4)

Supplementary Table 5: All vessel metrics across selected genes. Definitions of metrics are given in **Supplementary Table 2**. The table cells have been shaded with lower values in red, intermediate values in white and larger values in green.


| gene | Fractal Dimension | Vessel Density | Average Width | Distance Tortuosity Mean | Squared Curvature Tortuosity Mean | Tortuosity Density Mean |
|----------------|-------------------|----------------|---------------|--------------------------|-----------------------------------|-------------------------|
| <i>ABCA4</i> | 1.33 | 7.65% | 184.81 | 4.81 | 61.6 | 0.71 |
| <i>ABCC6</i> | 1.37 | 8.07% | 196.68 | 6.17 | 80.7 | 0.73 |
| <i>BBS1</i> | 1.18 | 4.56% | 186.86 | 9.66 | 214.9 | 0.7 |
| <i>BEST1</i> | 1.38 | 9.62% | 203.18 | 4.46 | 49.4 | 0.71 |
| <i>CACNA1F</i> | 1.21 | 5.35% | 218.03 | 9.24 | 83.8 | 0.73 |
| <i>CDH23</i> | 1.05 | 2.46% | 198.91 | 7.97 | 177.8 | 0.68 |
| <i>CERKL</i> | 1.16 | 3.51% | 179.55 | 7.2 | 95.8 | 0.67 |
| <i>CHM</i> | 1.3 | 6.20% | 190.34 | 6.14 | 104.4 | 0.69 |
| <i>CNGA3</i> | 1.24 | 5.36% | 209.19 | 5.17 | 70.9 | 0.7 |
| <i>CNGB3</i> | 1.24 | 5.92% | 205.53 | 6.42 | 67.1 | 0.7 |
| <i>CRB1</i> | 1.11 | 4.27% | 178.82 | 7.2 | 83.2 | 0.69 |
| <i>CRX</i> | 1.33 | 7.30% | 192.4 | 9.58 | 119.5 | 0.72 |
| <i>EFEMP1</i> | 1.43 | 10.06% | 208.55 | 4.31 | 39.4 | 0.72 |
| <i>EYS</i> | 1.16 | 3.07% | 172.31 | 7.39 | 108.3 | 0.69 |
| <i>GUCY2D</i> | 1.29 | 6.91% | 197.87 | 5.41 | 64.4 | 0.72 |
| <i>MYO7A</i> | 1.09 | 2.70% | 182.09 | 11 | 296.8 | 0.7 |
| <i>NR2E3</i> | 1.32 | 8.33% | 202.83 | 5.85 | 77.5 | 0.72 |
| <i>PDE6B</i> | 1.12 | 3.00% | 181.7 | 7.22 | 113.4 | 0.71 |
| <i>PROM1</i> | 1.26 | 6.10% | 179.6 | 6.5 | 116.9 | 0.72 |
| <i>PRPF31</i> | 1.21 | 4.10% | 178.26 | 7.11 | 146.2 | 0.7 |
| <i>PRPH2</i> | 1.36 | 8.00% | 184.62 | 4.76 | 52.1 | 0.71 |
| <i>RDH12</i> | 0.99 | 2.93% | 179.48 | 3.48 | 20.6 | 0.72 |
| <i>RHO</i> | 1.22 | 4.47% | 175.72 | 6.49 | 86.1 | 0.69 |
| <i>RP1</i> | 1.23 | 4.59% | 174.37 | 6.93 | 139.4 | 0.7 |
| <i>RP2</i> | 1.19 | 3.65% | 181.19 | 6.83 | 109.3 | 0.69 |
| <i>RPE65</i> | 0.97 | 2.04% | 164.35 | 6.64 | 110.8 | 0.65 |
| <i>RPGR</i> | 1.19 | 4.06% | 182.93 | 8.03 | 126.1 | 0.7 |
| <i>RS1</i> | 1.34 | 8.69% | 207.5 | 5.45 | 62.3 | 0.72 |
| <i>TIMP3</i> | 1.39 | 9.15% | 198.27 | 4.99 | 71.9 | 0.71 |
| <i>USH2A</i> | 1.17 | 3.42% | 170.22 | 7.26 | 101.6 | 0.69 |
| All | 1.25 | 5.75% | 186.52 | 6.45 | 98 | 0.7 |

Supplementary Table 6: Average increase in hypo-AF area stratified by ABCA4 variant severity. ABCA4 patients are grouped based on the severity of their genetic variants as proposed by Cornelis et al. 2022 into groups A, B and C²³.


| ABCA4 severity classification | Number of Patients | Variant combination | Average increase in hypo-AF area per year (mm ²) | Average increase in sqrt hypo-AF area per year (mm) |
|-------------------------------|--------------------|--|--|---|
| A | 69 | Severe/Severe | 3.11 | 0.29 |
| B | 75 | Intermediate/Intermediate or Severe/Intermediate | 1.59 | 0.17 |
| C | 184 | Mild/* | 0.87 | 0.11 |



Supplementary Figure 3: Rate of progression of hypo-AF in mm² per year for patients in the three severity classification groups of ABCA4. Note that Group A has a higher mean rate of progression than groups B and C, as it corresponds to the group with the highest severity. Error bars denote standard error.











Supplementary Figure 4: Comparison of the mean per-patient extent of macular ring present for patients with different variants (i.e. patients with at least one copy of the given variant) in *ABCA4*. Axes are truncated to exclude 99th percentile outliers. Most variants of *ABCA4* are not associated with a macular ring of raised AF, apart from p.(Gly1961Glu) which we see reflected in the different distributions of ring area in our data.




Supplementary Figure 5: hypo-AF area within 1.5mm of the fovea compared to LogMAR best corrected visual acuity (BCVA) where higher values corresponds to poorer acuity. Axes rescaled to 90th pct of data for legibility. Each circle represents a single patient with mean value across images. Least-squares regression line in red ($\beta=0.083$, $p<0.001$). Mean values for select genes are indicated by red crosses. Comparing hypo-AF


area within 1.5mm of the fovea and LogMAR best corrected visual acuity (BCVA) showed a positive statistical association ($\beta=0.083$, $p<0.001$). However, some genes demonstrated a different relationship from the main trend. For example, in *ABCA4* a worse BCVA was observed than might be expected from hypo-AF coverage, likely because *ABCA4*-associated retinopathy usually initially affects the fovea/central macula. By contrast, *CHM* typically exhibits a spared foveal island despite having significant areas of atrophy, thus accounting for the relatively preserved BCVA.

| | IR Scan and Vessels | Unregistered FAF Scans and Vessels | Overlap of IR and Registered FAF (Scans) | Overlap of IR and Registered FAF (Vessels) |
|---------|--|--|---|--|
| Scans |  |  |  |  |
| Vessels |  |  |  |  |

Supplementary Figure 6: Example showing how vessel tree segmentation improves cross-modality image registration. First row shows the individual and overlaid images, and second rows shows corresponding segmented vessel masks. For the overlaid images, the IR image is rendered in red, while the FAF image is rendered in green, enabling overlap to be assessed by looking at the correspondence between the two-colour channels. Vessel trees were extracted using AIRDetect for both the IR and the FAF image. Results of automatic registration directly on the raw images (scans column) and registration on the vessel trees (vessels column) are shown. In both cases this registration was performed using the SimpleElastix package. As shown by the final column, registering using vessel trees results in better overlap than registering using images alone.



Supplementary Figure 7: 55-degree FAF image with 0.5mm, 1.5mm, and 3mm radial distances shown (corresponding to 1mm, 3mm, and 6mm diameter ETDRS regions), and scale bar with 1mm gradations.



Supplementary Figure 8: Distributions of best corrected visual acuity (in LogMar) with respect to 36 genes sorted by the median of the visual acuity distribution per gene. Low vision is defined as a best-corrected visual acuity worse than 0.5 LogMAR but equal or better than 1.3 LogMAR in the better eye. Blindness is defined as a best-corrected visual acuity worse than 1.3 LogMAR. Also represented are Logmar of 1.98 (Counting Fingers), 2.28 (Hand Movement) and 2.7 (Light Perception).

References

1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. *BMJ Open* 2014;4:e004015. Available at: <http://bmjopen.bmj.com/content/4/2/e004015> [Accessed December 4, 2017].
2. Glatz M, Riedl R, Glatz W, et al. Blindness and visual impairment in Central Europe. *PLoS One* 2022;17:e0261897. Available at: <http://dx.doi.org/10.1371/journal.pone.0261897>.
3. Pontikos N, Arno G, Jurkute N, et al. Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom. *Ophthalmology* 2020;127:1384–1394. Available at: <http://dx.doi.org/10.1016/j.ophtha.2020.04.008>.
4. Georgiou M, Robson AG, Fujinami K, et al. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. *Prog Retin Eye Res* 2024;100:101244. Available at: <http://dx.doi.org/10.1016/j.preteyeres.2024.101244>.
5. Lee KE, Pulido JS, da Palma MM, et al. A Comprehensive Report of Intrinsically Disordered Regions in Inherited Retinal Diseases. *Genes* 2023;14. Available at: <http://dx.doi.org/10.3390/genes14081601>.
6. Daich Varela M, Esener B, Hashem SA, et al. Structural evaluation in inherited retinal diseases. *Br J Ophthalmol* 2021;105:1623–1631. Available at: <http://dx.doi.org/10.1136/bjophthalmol-2021-319228>.
7. Delori FC, Dorey CK, Staurenghi G, et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. *Invest Ophthalmol Vis Sci* 1995;36:718–729. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7890502>.
8. Strauss RW, Kong X, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11. *JAMA Ophthalmol* 2019;137:1134–1145. Available at: <http://dx.doi.org/10.1001/jamaophthalmol.2019.2885>.
9. Daich Varela M, Laich Y, Hashem SA, et al. Prognostication in Stargardt Disease Using Fundus Autofluorescence: Improving Patient Care. *Ophthalmology* 2023;130:1182–1190. Available at: <http://dx.doi.org/10.1016/j.ophtha.2023.06.010>.
10. Wang Y-Z, Juroch K, Chen Y, et al. Deep Learning-Facilitated Study of the Rate of Change in Photoreceptor Outer Segment Metrics in RPGR-Related X-Linked Retinitis Pigmentosa. *Invest Ophthalmol Vis Sci* 2023;64:31. Available at: <http://dx.doi.org/10.1167/iovs.64.14.31>.
11. Chang J, Xiao D, Mehdizadeh M, et al. Deep learning segmentation of hyperautofluorescent fleck lesions in Stargardt disease. *Sci Rep* 2020;10:16491. Available at: <http://dx.doi.org/10.1038/s41598-020-73339-y>.
12. Lin S, Vermeirsch S, Pontikos N, et al. Spectrum of genetic variants in the commonest genes causing inherited retinal disease in a large molecularly characterised UK cohort. *Ophthalmology Retina* 2024. Available at: <https://www.sciencedirect.com/science/article/pii/S2468653024000137>.
13. Nguyen Q, Woof W, Kabiri N, et al. Can artificial intelligence accelerate the diagnosis of inherited retinal diseases? Protocol for a data-only retrospective cohort study (Eye2Gene). *BMJ Open* 2023;13:e071043. Available at: <http://dx.doi.org/10.1136/bmjopen-2022-071043>.
14. Dice LR. Measures of the Amount of Ecologic Association Between Species. *Ecology* 1945;26:297–302.

Available at: <http://www.jstor.org/stable/1932409>.

15. Kuehlewein L, Hariri AH, Ho A, et al. Comparison of manual and semiautomated fundus autofluorescence analysis of macular atrophy in Stargardt disease phenotype. *Retina* 2016;36:1216–1221. Available at: <http://dx.doi.org/10.1097/IAE.0000000000000870>.

16. Strauss RW, Muñoz B, Jha A, et al. Comparison of short-wavelength reduced-illuminance and conventional autofluorescence imaging in Stargardt macular dystrophy. *Am J Ophthalmol* 2016;168:269–278. Available at: <http://dx.doi.org/10.1016/j.ajo.2016.06.003>.

17. Isensee F, Jaeger PF, Kohl SAA, et al. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. *Nat Methods* 2021;18:203–211. Available at: <http://dx.doi.org/10.1038/s41592-020-01008-z>.

18. Valmaggia P, Friedli P, Hörmann B, et al. Feasibility of Automated Segmentation of Pigmented Choroidal Lesions in OCT Data With Deep Learning. *Transl Vis Sci Technol* 2022;11:25. Available at: <http://dx.doi.org/10.1167/tvst.11.9.25>.

19. Zhang Q, Sampani K, Xu M, et al. AOSLO-net: A Deep Learning-Based Method for Automatic Segmentation of Retinal Microaneurysms From Adaptive Optics Scanning Laser Ophthalmoscopy Images. *Transl Vis Sci Technol* 2022;11:7. Available at: <http://dx.doi.org/10.1167/tvst.11.8.7>.

20. Zhang G, Fu DJ, Liefers B, et al. Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study. *Lancet Digit Health* 2021;3:e665–e675. Available at: [http://dx.doi.org/10.1016/S2589-7500\(21\)00134-5](http://dx.doi.org/10.1016/S2589-7500(21)00134-5).

21. Beucher S, Meyer F. The morphological approach to segmentation: The watershed transformation. In: *Mathematical Morphology in Image Processing*. CRC Press; 2018:433–481. Available at: <https://www.taylorfrancis.com/chapters/edit/10.1201/9781482277234-12/morphological-approach-segmentation-watershed-transformation-beucher-meyer>.

22. Zhou Y, Wagner SK, Chia MA, et al. AutoMorph: Automated Retinal Vascular Morphology Quantification Via a Deep Learning Pipeline. *Transl Vis Sci Technol* 2022;11:12. Available at: <http://dx.doi.org/10.1167/tvst.11.7.12>.

23. Cornelis SS, Runhart EH, Bauwens M, et al. Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity. *Am J Hum Genet* 2022;109:498–507. Available at: <http://dx.doi.org/10.1016/j.ajhg.2022.01.008>.

24. Cornelis SS, Bauwens M, Haer-Wigman L, et al. Compendium of clinical variant classification for 2,247 unique ABCA4 variants to improve genetic medicine access for Stargardt Disease. *bioRxiv* 2023. Available at: <https://www.medrxiv.org/content/10.1101/2023.04.24.23288782v1>.

25. Fakin A, Robson AG, Fujinami K, et al. Phenotype and Progression of Retinal Degeneration Associated With Nullizigosity of ABCA4. *Invest Ophthalmol Vis Sci* 2016;57:4668–4678. Available at: <http://dx.doi.org/10.1167/iovs.16-19829>.

26. Georgiou M, Kane T, Tanna P, et al. Prospective Cohort Study of Childhood-Onset Stargardt Disease: Fundus Autofluorescence Imaging, Progression, Comparison with Adult-Onset Disease, and Disease Symmetry. *Am J Ophthalmol* 2020;211:159–175. Available at: <http://dx.doi.org/10.1016/j.ajo.2019.11.008>.

27. Fujinami K, Zernant J, Chana RK, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. *Ophthalmology* 2015;122:326–334. Available at: <http://dx.doi.org/10.1016/j.optha.2014.08.012>.

28. Fujinami K, Lois N, Mukherjee R, et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. *Invest Ophthalmol Vis Sci* 2013;54:8181–

8190. Available at: <http://dx.doi.org/10.1167/iovs.13-12104>.

29. Khan KN, Kasilian M, Mahroo OAR, et al. Early Patterns of Macular Degeneration in ABCA4-Associated Retinopathy. *Ophthalmology* 2018;125:735–746. Available at: <http://dx.doi.org/10.1016/j.ophtha.2017.11.020>.

30. Zinkernagel MS, MacLaren RE. Recent advances and future prospects in choroideremia. *Clin Ophthalmol* 2015;9:2195–2200. Available at: <http://dx.doi.org/10.2147/OPHTH.S65732>.

31. Syed R, Sundquist SM, Ratnam K, et al. High-resolution images of retinal structure in patients with choroideremia. *Invest Ophthalmol Vis Sci* 2013;54:950–961. Available at: <http://dx.doi.org/10.1167/iovs.12-10707>.

32. Fujinami K, Sergouniotis PI, Davidson AE, et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. *Am J Ophthalmol* 2013;156:487-501.e1. Available at: <http://dx.doi.org/10.1016/j.ajo.2013.05.003>.

33. Shiraki K, Kohno T, Moriwaki M, Yanagihara N. Fundus autofluorescence in patients with pseudoxanthoma elasticum. *Int Ophthalmol* 2001;24:243–248. Available at: <https://pubmed.ncbi.nlm.nih.gov/14531624/> [Accessed March 24, 2024].

34. Sparrow JR, Duncker T, Woods R, Delori FC. Quantitative Fundus Autofluorescence in Best Vitelliform Macular Dystrophy: RPE Lipofuscin is not Increased in Non-Lesion Areas of Retina. In: *Retinal Degenerative Diseases*. Springer International Publishing; 2016:285–290. Available at: http://dx.doi.org/10.1007/978-3-319-17121-0_38.

35. Shah M, Broadgate S, Shanks M, et al. Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations. *JAMA Ophthalmol* 2020. Available at: <http://dx.doi.org/10.1001/jamaophthalmol.2020.0666>.

36. Laich Y, Georgiou M, Fujinami K, et al. Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings. *Ophthalmology* 2024. Available at: <http://dx.doi.org/10.1016/j.ophtha.2024.01.027>.

37. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet* 2006;368:1795–1809. Available at: <https://pubmed.ncbi.nlm.nih.gov/17113430/> [Accessed March 24, 2024].

38. Cideciyan AV, Jacobson SG. Leber congenital amaurosis (LCA): Potential for improvement of vision. *Invest Ophthalmol Vis Sci* 2019;60:1680. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892385/> [Accessed March 24, 2024].

39. Huang D, Heath Jeffery RC, Aung-Htut MT, et al. Stargardt disease and progress in therapeutic strategies. *Ophthalmic Genet* 2022;43:1–26. Available at: <http://dx.doi.org/10.1080/13816810.2021.1966053>.

40. Lee W, Zernant J, Nagasaki T, et al. Cis-acting modifiers in the ABCA4 locus contribute to the penetrance of the major disease-causing variant in Stargardt disease. *Hum Mol Genet* 2021;30:1293–1304. Available at: <http://dx.doi.org/10.1093/hmg/ddab122>.

41. Fujinami K, Sergouniotis PI, Davidson AE, et al. The clinical effect of homozygous ABCA4 alleles in 18 patients. *Ophthalmology* 2013;120:2324–2331. Available at: <http://dx.doi.org/10.1016/j.ophtha.2013.04.016>.

42. Fakin A, Robson AG, Chiang JP-W, et al. The Effect on Retinal Structure and Function of 15 Specific ABCA4 Mutations: A Detailed Examination of 82 Hemizygous Patients. *Invest Ophthalmol Vis Sci* 2016;57:5963–5973. Available at: <http://dx.doi.org/10.1167/iovs.16-20446>.

43. Grob S, Yonekawa Y, Elliott D. Multimodal imaging of adult-onset foveomacular vitelliform dystrophy. *Saudi J Ophthalmol* 2014;28:104–110. Available at: <http://dx.doi.org/10.1016/j.sjopt.2014.02.001>.

44. Strauss RW, Ho A, Jha A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No. 17). *Am J Ophthalmol* 2023;250:157–170. Available at: <http://dx.doi.org/10.1016/j.ajo.2023.02.003>.
45. Antonelli G, Parravano M, Barbano L, et al. Multimodal Study of PRPH2 Gene-Related Retinal Phenotypes. *Diagnostics (Basel)* 2022;12. Available at: <http://dx.doi.org/10.3390/diagnostics12081851>.
46. Daich Varela M, Georgiadis A, Michaelides M. Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes. *Br J Ophthalmol* 2023;107:1223–1230. Available at: <http://dx.doi.org/10.1136/bjo-2022-321903>.
47. Miere A, Le Meur T, Bitton K, et al. Deep Learning-Based Classification of Inherited Retinal Diseases Using Fundus Autofluorescence. *J Clin Med Res* 2020;9. Available at: <http://dx.doi.org/10.3390/jcm9103303>.
48. Miere A, Capuano V, Kessler A, et al. Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. *Comput Biol Med* 2021;130:104198. Available at: <http://dx.doi.org/10.1016/j.compbiomed.2020.104198>.
49. Pontikos N, Woof W, Veturi A, et al. Eye2Gene: prediction of causal inherited retinal disease gene from multimodal imaging using deep-learning. *Research Square* 2022. Available at: <https://www.researchsquare.com/article/rs-2110140/latest> [Accessed March 11, 2024].
50. Fujinami-Yokokawa Y, Ninomiya H, Liu X, et al. Prediction of causative genes in inherited retinal disorder from fundus photography and autofluorescence imaging using deep learning techniques. *British Journal of Ophthalmology* 2021;105:1272–1279. Available at: <http://dx.doi.org/10.1136/bjophthalmol-2020-318544>.
51. Lambertus S, Lindner M, Bax NM, et al. Progression of Late-Onset Stargardt Disease. *Invest Ophthalmol Vis Sci* 2016;57:5186–5191. Available at: <http://dx.doi.org/10.1167/iovs.16-19833>.
52. Ervin A-M, Strauss RW, Ahmed MI, et al. A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned. *Transl Vis Sci Technol* 2019;8:16. Available at: <http://dx.doi.org/10.1167/tvst.8.2.16>.
53. Strauss RW, Muñoz B, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9). *JAMA Ophthalmol* 2017;135:1232–1241. Available at: <http://dx.doi.org/10.1001/jamaophthalmol.2017.4152>.
54. Heath Jeffery RC, Thompson JA, Lo J, et al. Atrophy Expansion Rates in Stargardt Disease Using Ultra-Widefield Fundus Autofluorescence. *Ophthalmol Sci* 2021;1:100005. Available at: <http://dx.doi.org/10.1016/j.xops.2021.100005>.
55. Zhao PY, Branham K, Schlegel D, et al. Automated Segmentation of Autofluorescence Lesions in Stargardt Disease. *Ophthalmol Retina* 2022;6:1098–1104. Available at: <http://dx.doi.org/10.1016/j.oret.2022.05.020>.
56. Hull S, Arno G, Plagnol V, et al. The phenotypic variability of retinal dystrophies associated with mutations in CRX, with report of a novel macular dystrophy phenotype. *Invest Ophthalmol Vis Sci* 2014;55:6934–6944. Available at: <http://dx.doi.org/10.1167/iovs.14-14715>.
57. Fujinami-Yokokawa Y, Fujinami K, Kuniyoshi K, et al. Clinical and Genetic Characteristics of 18 Patients from 13 Japanese Families with CRX-associated retinal disorder: Identification of Genotype-phenotype Association. *Sci Rep* 2020;10:9531. Available at: <http://dx.doi.org/10.1038/s41598-020-65737-z>.
58. Fujinami-Yokokawa Y, Yang L, Joo K, et al. Occult Macular Dysfunction Syndrome: Identification of Multiple Pathologies in a Clinical Spectrum of Macular Dysfunction with Normal Fundus in East Asian Patients: EAOMD Report No. 5. *Genes* 2023;14. Available at: <http://dx.doi.org/10.3390/genes14101869>.

59. Awadh Hashem S, Georgiou M, Ali RR, Michaelides M. RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy. *Cold Spring Harb Perspect Med* 2023. Available at: <http://dx.doi.org/10.1101/cshperspect.a041280>.
60. Tee JJJ, Kalitzeos A, Webster AR, et al. QUANTITATIVE ANALYSIS OF HYPERAUTOFLUORESCENT RINGS TO CHARACTERIZE THE NATURAL HISTORY AND PROGRESSION IN RPGR-ASSOCIATED RETINOPATHY. *Retina* 2018;38:2401–2414. Available at: <http://dx.doi.org/10.1097/IAE.0000000000001871>.
61. Cideciyan AV, Swider M, Aleman TS, et al. Reduced-illuminance autofluorescence imaging in ABCA4-associated retinal degenerations. *J Opt Soc Am A Opt Image Sci Vis* 2007;24:1457–1467. Available at: <http://dx.doi.org/10.1364/josaa.24.001457>.
62. Shi C, Lee J, Wang G, et al. Assessment of image quality on color fundus retinal images using the automatic retinal image analysis. *Sci Rep* 2022;12:10455. Available at: <http://dx.doi.org/10.1038/s41598-022-13919-2>.
63. Hart WE, Goldbaum M, Côté B, et al. Measurement and classification of retinal vascular tortuosity. *Int J Med Inform* 1999;53:239–252. Available at: [http://dx.doi.org/10.1016/s1386-5056\(98\)00163-4](http://dx.doi.org/10.1016/s1386-5056(98)00163-4).
64. Grisan E, Foracchia M, Ruggeri A. A novel method for the automatic grading of retinal vessel tortuosity. *IEEE Trans Med Imaging* 2008;27:310–319. Available at: <http://dx.doi.org/10.1109/TMI.2007.904657>.